Executives
1Board of Directors
6SpinalMotion Management Team
1 Team Member
SpinalMotion has 1 executive. SpinalMotion's former Chief Executive Officer, President is David Hovda.
Name | Work History | Title | Status |
|---|---|---|---|
David Hovda | Chief Executive Officer, President | Former |
Name | David Hovda |
|---|---|
Work History | |
Title | Chief Executive Officer, President |
Status | Former |
This profile has not been claimed.
Highlight your management team’s expertise.
SpinalMotion Board of Directors
6 Board of directors
SpinalMotion has 6 board of directors, including Glenn Reicin.
Name | Firm | Work History | Other Seats |
|---|---|---|---|
Glenn Reicin | Glenn Reicin, joined Alladapt as Chief Financial Officer in June 2021. Prior to Alladapt Mr. Reicin was Chief Financial Officer at Sigilon Therapeutics, Inc., a provider of novel treatments for a range of chronic diseases where he "quarterbacked" the company's crossover financing and public offering. From 2013 to May 2019, Mr. Reicin served as President of Greyrock Biomedical Advisors, which provided a range of deal sourcing, valuation, due diligence and management consulting services for companies in the healthcare space. Most notably, he designed and implemented a strategy for PDL Biopharma to ensure the profitability of the company after a 2016 patent and corresponding royalty expired. Previously, in 2013, he served as an Executive-in-Resident at Covidien and from 2008 to 2012 as Managing Director at Skyline Ventures. At Skyline Ventures, he served as an active board member at a number of biotech firms. He started his career at Morgan Stanley where he became a Managing Director in equity research covering medical technology. His sell-side career spanned 18 years, including 15 years as a top-three ranked analyst and six consecutive years in the top spot. Mr. Reicin holds an M.B.A. from Harvard Business School and B.A. from Brandeis University. | SpinalMotion | |
James Shapiro | SpinalMotion | ||
Mike Ellwein | SpinalMotion | ||
Richard Spalding | SpinalMotion | ||
Stephen Sullivan | SpinalMotion |
Name | Glenn Reicin | James Shapiro | Mike Ellwein | Richard Spalding | Stephen Sullivan |
|---|---|---|---|---|---|
Firm | |||||
Work History | Glenn Reicin, joined Alladapt as Chief Financial Officer in June 2021. Prior to Alladapt Mr. Reicin was Chief Financial Officer at Sigilon Therapeutics, Inc., a provider of novel treatments for a range of chronic diseases where he "quarterbacked" the company's crossover financing and public offering. From 2013 to May 2019, Mr. Reicin served as President of Greyrock Biomedical Advisors, which provided a range of deal sourcing, valuation, due diligence and management consulting services for companies in the healthcare space. Most notably, he designed and implemented a strategy for PDL Biopharma to ensure the profitability of the company after a 2016 patent and corresponding royalty expired. Previously, in 2013, he served as an Executive-in-Resident at Covidien and from 2008 to 2012 as Managing Director at Skyline Ventures. At Skyline Ventures, he served as an active board member at a number of biotech firms. He started his career at Morgan Stanley where he became a Managing Director in equity research covering medical technology. His sell-side career spanned 18 years, including 15 years as a top-three ranked analyst and six consecutive years in the top spot. Mr. Reicin holds an M.B.A. from Harvard Business School and B.A. from Brandeis University. | ||||
Other Seats | SpinalMotion | SpinalMotion | SpinalMotion | SpinalMotion | SpinalMotion |
Compare SpinalMotion to Competitors
Theken Disc, LLC founded in 2003 designs, develops and manufactures spinal arthroplasty products, such as the eDisc, a microelectronic artificial spinal disc replacement.
Spinal Restoration restores patients' lives by delivering new therapies that address unmet needs in spine health management. These therapies are minimally invasive, early interventions with clinically proven results. The company is working with a diverse, highly regarded group of clinical and scientific advisors to develop and gain regulatory approval of the Biostat System, a proprietary resorbable biologic and delivery system for the treatment of chronic disc pain, based on solid scientific and clinical evidence.
CAdisc is a unique, entirely polymeric Total Disc Replacement system for the treatment of degenerative disc disease in the lumbar and cervical spine. CAdisc-Lchar(2122) is designed to relieve pain and restore physiological quality of motion in the lumbar spine.
Gentis is a developer of minimally invasive, biomaterials-based products intended to treat the early-stage degeneration of the spine, which causes back pain. The company's first patented product, DiscCell, is a breakthrough injectable biomaterial that augments or replaces the diseased nucleus pulposus of the spinal disc.
Axial Biotech, founded in 2002 by a group of spine surgeons and geneticists, is focused on the use of genetics and the development of minimally invasive fusionless devices to advance the diagnosis and treatment of diseases and deformities of the human spine. Axial is a company to pursue DNA-based pre-symptomatic and prognostic tests for common spinal conditions which will augment current clinical and surgical practices. In its initial genetic product development initiative, Axial has made progress towards the discovery of a location in the human genome that is associated with adolescent idiopathic scoliosis. In addition, Axial's founders have developed five motion preserving, fusionless surgical devices (including such device currently being implanted in humans) that have the promise of expanding the current treatable scoliosis patient population by a factor of ten. Axial intends to use its genetic intellectual property in the development of bio-mechanical devices, and to apply its gene discovery/product development methodology to other spinal diseases. Axial (www.axialbiotech.com) is located in Salt Lake City, Utah.
Disc Dynamics has developed the DASCORTM Disc Arthroplasty System, an innovative, minimally invasive nucleus replacement treatment for patients suffering from chronic low back pain caused by Degenerative Disc Disease (DDD).
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.